Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07033026 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
A Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer, sponsored by NGM Biopharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT07033026 is a Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer that is actively recruiting participants, run by NGM Biopharmaceuticals. The registered enrollment target is 136 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07033026, a Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer, is actively recruiting participants, sponsored by NGM Biopharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Conditions Studied
Interventions
- DRUG NGM120 Q4W
- DRUG NGM120 Q8W
- DRUG Placebo given
Study Locations (1)
Texas
- NGM Clinical Study Site - Laredo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07033026
The ClinicalTrials.gov registry entry for NCT07033026 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which NGM120 Q4W is the first listed.
NCT07033026 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07033026 about?
NCT07033026 is a clinical study titled "An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.". A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
What is the current status of trial NCT07033026?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2025-06. Estimated completion is 2027-12.
What conditions does trial NCT07033026 study?
This clinical trial studies the following conditions: Colorectal Cancer, CRC, Colorectal Cancer, Cancer Cachexia.
What interventions are being tested in trial NCT07033026?
The interventions under investigation include: NGM120 Q4W (DRUG), NGM120 Q8W (DRUG), Placebo given (DRUG).
Who is sponsoring clinical trial NCT07033026?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07033026 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.